Shilanski & Associates’s Humana HUM Stock Holding History

Shilanski & Associates’s Portfolio HUM Stock Details HUM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-715	Closed	-$347K	–	139
2022 Q3	$347K	Buy	+715	New	+$348K	0.13%	87

Other funds holding HUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Shilanski & Associates's HUM Position: Q4 2022 in Review

Shilanski & Associates sold out of Humana (HUM) in Q4 2022, closing a stake of 715 shares — an estimated $347K sold.

Shilanski & Associates first reported a position in HUM in Q3 2022 and held it in 1 quarter. The position peaked at $347K in Q3 2022. 1,077 funds tracked by Wall St. Rank hold HUM as of Q4 2022.

Shilanski & Associates reported no remaining Humana position as of Q4 2022 after selling out during the quarter.
Shilanski & Associates sold 715 Humana shares in Q4 2022, an estimated $347K.
Shilanski & Associates first reported a position in Humana in Q3 2022 and held it in 1 quarter.
Shilanski & Associates's Humana position peaked at $347K in Q3 2022.
1,077 funds tracked by Wall St. Rank held Humana as of Q4 2022.

Based on Shilanski & Associates's 13F filing for Q4 2022, filed 31 Jan 2023.